Anbesol Cold Sore Therapy Availability: What Providers and Prescribers Need to Know in 2026

Healthcare providers and prescribers are increasingly fielding questions from patients who cannot find Anbesol Cold Sore Therapy — a widely used OTC topical ointment for fever blister and cold sore pain relief. While this is an OTC product, provider awareness of its availability status, ingredient profile, and appropriate alternatives is valuable for patient counseling. Here is what clinicians need to know in 2026.

Product Overview and Clinical Pharmacology

Anbesol Cold Sore Therapy is a multi-ingredient topical ointment manufactured by Haleon US Services. It is indicated for temporary relief of pain associated with fever blisters and cold sores, and for relieving dryness and softening lesions. Its active ingredients and mechanisms include:

• Benzocaine 20%: Local anesthetic. Blocks sodium channels in peripheral nerve endings, preventing depolarization and pain signal transmission. Highest OTC benzocaine concentration available in a cold sore product.
• Camphor 3%: Counter-irritant and mild anesthetic. Stimulates cold receptors (TRPM8) in skin to provide a cooling sensation and reduce itching and pain perception.
• Allantoin 1%: Keratolytic and skin protectant. Promotes keratinocyte proliferation and wound healing, softens the lesion crust, and reduces irritation.
• White petrolatum 64.9%: Occlusive skin protectant. Forms a physical barrier over the lesion, preventing water loss, protecting against environmental irritants, and creating a moist microenvironment conducive to healing.

The product is classified as an OTC drug under FDA's monograph system for topical anesthetics and skin protectants. It does not require a prescription and is not a controlled substance. Systemic absorption is minimal from topical application to intact or mildly compromised skin.

Key Safety Consideration: Methemoglobinemia Risk

The most significant safety concern with this product is benzocaine-induced methemoglobinemia. Benzocaine oxidizes hemoglobin iron from Fe2+ to Fe3+, forming methemoglobin, which cannot carry oxygen. This can reduce oxygen delivery to tissues. Methemoglobinemia from topical benzocaine is rare but can be serious and potentially fatal.

Risk factors include: G6PD deficiency, methemoglobin reductase deficiency, concomitant use of other methemoglobin-inducing agents (dapsone, nitrites, certain antibiotics), and application over large surface areas. Patients presenting with cyanosis, headache, tachycardia, dyspnea, or altered mentation after benzocaine use should be evaluated for methemoglobinemia.

The FDA issued a warning in 2018 and continues to advise against benzocaine use in children under 2 years. The label on Anbesol Cold Sore Therapy reflects this warning: the product is contraindicated for children under 2.

Availability Status in 2026

There is no FDA-declared shortage of Anbesol Cold Sore Therapy in 2026. The product continues to be manufactured and distributed by Haleon US Services. However, clinicians should be aware that their patients may encounter localized stockouts at specific pharmacy locations, especially during peak cold sore seasons (winter and summer). This is a retail distribution and inventory management issue rather than a manufacturing failure.

Patients most at risk for difficulty finding the product include those in rural areas with limited pharmacy access, those reliant on small independent pharmacies that may not stock the product, and patients during high-demand seasonal windows.

Therapeutic Alternatives to Recommend

When counseling patients who cannot find Anbesol Cold Sore Therapy, consider the following alternatives stratified by clinical goal:

• Pain relief (OTC): Orajel Cold Sore Treatment (benzocaine 5% + benzalkonium chloride 0.13%), Carmex Cold Sore Treatment (benzocaine + camphor + menthol)
• Antiviral / shortening healing time (OTC): Abreva (docosanol 10%) — the only FDA-approved OTC product demonstrated to shorten cold sore healing time. Must be applied at prodrome stage for optimal benefit.
• Prescription antivirals (episodic): Acyclovir 400 mg TID x 5 days, or valacyclovir 2 g BID x 1 day (1-day regimen). For patients with ≥6 outbreaks per year, consider daily suppressive therapy.
• Topical acyclovir (Rx): Acyclovir 5% cream or ointment — less effective than oral antivirals for herpes labialis but an option when oral therapy is contraindicated or unavailable.

Counseling Points for Patients About Anbesol Cold Sore Therapy

When patients report using or seeking Anbesol Cold Sore Therapy, key counseling points include:

• Apply no more than 3–4 times per day; do not exceed recommended dosage
• For external use only; avoid contact with eyes
• Stop use and seek medical attention if signs of methemoglobinemia appear (cyanosis, headache, tachycardia, dyspnea, dizziness)
• Do not use in children under 2; adult supervision required for children under 12
• Contraindicated in patients with known allergy to 'caine' anesthetics (procaine, butacaine, benzocaine)
• Anbesol Cold Sore Therapy treats symptoms only — it does not eliminate the herpes simplex virus or prevent recurrence

Resources for Providers to Share with Patients

Providers who want to help patients locate Anbesol Cold Sore Therapy or similar OTC products when stock is unavailable can recommend medfinder for providers. medfinder calls pharmacies near the patient to find which ones have the needed medication in stock, saving patients the time and frustration of calling pharmacy after pharmacy. This is particularly valuable for patients with limited mobility or those in areas with few pharmacy options.